Home About us Editorial board Search Ahead of print Current issue Archives Submit article Instructions Subscribe Contacts Login 
  Home Print this page Email this page Small font sizeDefault font sizeIncrease font size Users Online: 658  

    Article Cited by others

ORIGINAL ARTICLE

Improved Quality of Life in Patients Treated with Peptide Radionuclides

Traub-Weidinger T, Raderer M, Uffmann M, Angelberger P, Kurtaran A, Leimer M, Preitfellner J, Dudczak R, Virgolini I

Year : 2011| Volume: 10| Issue : 2 | Page no: 115-121

   This article has been cited by
 
1 Peptide receptor radionuclide therapy with 177Lu-DOTA-TATE as a promising treatment of malignant insulinoma: a series of case reports and literature review
D. Magalhães,I. L. Sampaio,G. Ferreira,P. Bogalho,D. Martins-Branco,R. Santos,H. Duarte
Journal of Endocrinological Investigation. 2018;
[Pubmed]  [Google Scholar] [DOI]
2 Peptide receptor radionuclide therapy of neuroendocrine tumours
Tessa Brabander,Jaap J.M. Teunissen,Casper H.J. Van Eijck,Gaston J.H. Franssen,Richard A. Feelders,Wouter W. de Herder,Dik J. Kwekkeboom
Best Practice & Research Clinical Endocrinology & Metabolism. 2015;
[Pubmed]  [Google Scholar] [DOI]
3 Is There a Role for Peptide Receptor Radionuclide Therapy in Medullary Thyroid Cancer?
Fernanda Vaisman,Paulo Henrique Rosado de Castro,Flavia Paiva Proença Lobo Lopes,Daniel Barretto Kendler,Cencita H.N. Pessoa,Daniel Alves Bulzico,Douglas de Carvalho Leal,Bruno Vilhena,Mario Vaisman,Michel Carneiro,Rossana Corbo
Clinical Nuclear Medicine. 2015; 40(2): 123
[Pubmed]  [Google Scholar] [DOI]
4 Paving the Way to Personalized Medicine: Production of Some Promising Theragnostic Radionuclides at Brookhaven National Laboratory
Suresh C. Srivastava
Seminars in Nuclear Medicine. 2012; 42(3): 151
[Pubmed]  [Google Scholar] [DOI]

 

Read this article